Conatus Pharmaceuticals Reports 2016 Financial Results and Program Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Conatus Pharmaceuticals (CNAT) Misses Q4 EPS by 9c
March 15, 2017 4:07 PM EDTConatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.35), $0.09 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $800 million versus the consensus estimate of $1.67 million.
For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.
... More